Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder

Journal of Neuroscience

Volumn 32, Issue 3, 2012, Pages 841-849

  Volkow, Nora D ^a,b   Wang, Gene Jack ^c   Tomasi, Dardo ^b   Kollins, Scott H ^d   Wigal, Tim L ^e   Newcorn, Jeffrey H ^f   Telang, Frank W ^b   Fowler, Joanna S ^c   Logan, Jean ^c   Wong, Christopher T ^b   Swanson, James M ^d  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; METHYLPHENIDATE; PLACEBO; RACLOPRIDE C 11;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERACTIVITY; LONG TERM CARE; MALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; TEMPORAL CORTEX; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BASAL GANGLIA; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPHENIDATE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RACLOPRIDE; RECEPTORS, DOPAMINE; STATISTICS AS TOPIC;

EID: 84862909203     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4461-11.2012     Document Type: Article

References (60)

1. Aghajanian GK, Bunney BS (1977) Dopamine "autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 297:1-7.
2. Alexoff DL, Shea C, Fowler JS, King P, Gatley SJ, Schlyer DJ, Wolf AP (1995) Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol 22:893-904.
3. Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23 [Suppl 1]:33-41.
4. 11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 63:1386-1395.
5. Bush G, Spencer TJ, Holmes J, Shin LM, Valera EM, Seidman LJ, Makris N, Surman C, Aleardi M, Mick E, Biederman J (2008) Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry 65:102-114.
6. Carboni E, Tanda GL, Frau R, Di ChiaraG (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070.
7. Castellanos FX (2009) Toward the dimensionome: parsing reward-related processing in attention-deficit/hyperactivity disorder. Biol Psychiatry 65:5-6.
8. Conners CK (1998) Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 59 [Suppl 7]:24-30.
9. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
10. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, Cunningham VJ, Grasby PM (2009) The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 33:1109-1132.
11. Fan J, McCandliss BD, Fossella J, Flombaum JI, Posner MI (2005) The activation of attentional networks. Neuroimage 26:471-479.
12. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lépine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402-409.
13. Forssberg H, Fernell E, Waters S, Waters N, Tedroff J (2006) Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. Behav Brain Funct 2:40.
14. Friston K, Holmes A, Worsley K, Poline J, Frith C, Frackowiak R (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210.
15. Gainetdinov RR, Caron MG (2003) Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43:261-284.
16. Gjedde A, Wong DF, Rosa-Neto P, Cumming P (2005) Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol 63:1-20.
17. Guy W (2000) Clinical global impression (CGI) scale. In: Handbook of psychiatric measures (Rush AJ, First MB, Blacker D, eds). Washington, DC: American Psychiatric Publishing.
18. Haenlein M, Caul WF (1987) Attention deficit disorder with hyperactivity: a specific hypothesis of reward dysfunction. J Am Acad Child Adolesc Psychiatry 26:356-362.
19. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
20. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
21. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS (2010) Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 68:854-860.
22. Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F (2007) Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Adv Ther 24:182-188.
23. Karreman M, Moghaddam B (1996) The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 66:589-598.
24. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716-723.
25. Kobel M, Bechtel N, Specht K, Klarhöfer M, Weber P, Scheffler K, Opwis K, Penner IK (2010) Structural and functional imaging approaches in attention deficit/hyperactivity disorder: does the temporal lobe play a key role? Psychiatry Res 183:230-236.
26. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037.
27. Lammel S, Hetzel A, Häckel O, Jones I, Liss B, Roeper J (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57:760-773.
28. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
29. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300.
30. Modi NB, Lindemulder B, Gupta SK (2000) Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 40: 379-388.
31. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR; MTA Cooperative Group (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48:484-500.
32. 11C]FLB 457 PET. J Cereb Blood Flow Metab 27:369-377.
33. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389-395.
34. National Institutes of Health (2000) National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J AmAcad Child Adolesc Psychiatry 39:182-193.
35. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653.
36. Prince J (2008) Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol 28:S39-S45.
37. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, Gjedde A (2005) Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 25:868-876.
38. Rösler M, Retz W, Stieglitz RD (2010) Psychopathological rating scales as efficacy parameters in adultADHDtreatment investigations: benchmarking instruments for international multicentre trials. Pharmacopsychiatry 43:92-98.
39. Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E (2009) Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology 57:640-652.
40. Sesack SR, Hawrylak VA, Guido MA, Levey AI (1998) Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 42:171-174.
41. Sonuga-Barke EJ (2003) The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 27:593-604.
42. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, Fischman AJ (2006) PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. AmJ Psychiatry 163:387-395.
43. 11C]-raclopride binding after THC challenge. Neuroimage 52: 1521-1527.
44. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T; MTACooperative Group (2008) Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA). Part II. Supporting details. J Atten Disord 12:15-43.
45. Tilley MR, Gu HH (2008) The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther 327:554-560.
46. Tripp G, Wickens JR (2008) Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. J Child Psychol Psychiatry 49:691-704.
47. 11C]raclopride in the human brain. Synapse 16:255-262.
48. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833.
49. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331.
50. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121(1-5).
51. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43:181-187.
52. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, Gatley SJ, Pappas N, Wong C, Vaska P, Zhu W, Swanson JM (2004) Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161:1173-1180.
53. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM (2007) Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64:932-940.
54. 11C]raclopride to dopamine D2/D3 receptors in the human brain. J Neurosci 28:8454-8461.
55. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM (2009) Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302:1084-1091.
56. Volkow ND, Wang GJ, Newcorn JH, Kollins SH, Wigal TL, Telang F, Fowler JS, Goldstein RZ, Klein N, Logan J, Wong C, Swanson JM (2011) Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Mol Psychiatry 16:1147-1154.
57. Wang GJ, Volkow ND, Levy AV, Fowler JS, Logan J, Alexoff D, Hitzemann RJ, Schyler DJ (1996) MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comput Assist Tomogr 20:423-428.
58. Wang GJ, Volkow ND, Wigal T, Kollins S, Newcorn J, Telang F, Logan J, Wong C, Fowler JS, Swanson J (2009) Chronic treatment with methylphenidate increases dopamine transporter density in patients with attention deficit hyperactive disorder. J Nucl Med 50 [Suppl 2]:1283.
59. 11C]raclopride in the human brain in response to methylphenidate. J Nucl Med 40:1285-1291.
60. Wise RA (2002) Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240.